"We are thrilled that our research involving our selective degrader programs for SMARCA2, CDK2 and IKZF2 will be showcased prominently at AACR 2025, including during two oral presentations ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...